International Journal of Immunotherapy and Cancer Research Submit Manuscript

    CNS-invasive aspergillosis following ibrutinib therapy

    DOI Logo 10.17352/2455-8591.000035

    Published On: December 08, 2022 | Pages: 001 - 003

    Author(s): Matthew Kurian*, Eric Vick and Dipen Khanapara

    ORCID Logo  0000-0003-4015-5261

    Ibrutinib is Bruton’s tyrosine kinase inhibitor that now become the standard of care for the treatment of CLL (chronic lymphocytic leukemia) and other lymphoid cancers. With its increasing usage, oncologists must become more aware of their potential side effect profile. Ibrutinib is typically thought to be less immunosuppressive than standard immunotherapy; however, c ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat
    Abstract View Full Article View



    Case Reports

    Help ? Google Reviews 11